Cargando…

Risk Factors for Mortality in Patients with Carbapenem-Resistant Acinetobacter baumannii Bacteremia: Impact of Appropriate Antimicrobial Therapy

This study investigated predictors associated with 14-day mortality, and focused especially on the impact of appropriate antimicrobial treatment among patients with carbapenem-resistant Acinetobacter baumannii (CRAB) bacteremia. This retrospective study was performed at a tertiary care hospital in K...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Youn Jeong, Kim, Sang Il, Hong, Kyung-Wook, Kim, Yang Ree, Park, Yeon Joon, Kang, Moon-Won
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Academy of Medical Sciences 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3342535/ https://www.ncbi.nlm.nih.gov/pubmed/22563209 http://dx.doi.org/10.3346/jkms.2012.27.5.471

Ejemplares similares

1855. Risk factors for early mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia
por: Lee, Chan Mi, et al.
Publicado: (2022)

Clinical and Microbiological Analysis of Risk Factors for Mortality in Patients With Carbapenem-Resistant Acinetobacter baumannii Bacteremia
por: Son, Hyo-Ju, et al.
Publicado: (2020)

Risk Factors for Occurrence and 30-Day Mortality for Carbapenem-Resistant Acinetobacter baumannii Bacteremia in an Intensive Care Unit
por: Kim, Song Yee, et al.
Publicado: (2012)

135. Clinical and Microbiologic Analysis of Risk Factors for Mortality in Patients with Carbapenem-Resistant Acinetobacter baumannii Bacteremia
por: Cho, Eunbeen, et al.
Publicado: (2019)

Comparison between bacteremia caused by carbapenem resistant Acinetobacter baumannii and Acinetobacter nosocomialis
por: Yang, Ya-Sung, et al.
Publicado: (2013)

O047: The effect of active surveillance culture of carbapenem resistant Acinetobacter baumannii on the occurrence of carbapenem resistant Acinetobacter baumannii bacteremia in a single intensive care unit
por: Kim, G, et al.
Publicado: (2013)

Natural prognosis of carbapenem-resistant Acinetobacter baumannii bacteremia in patients who did not receive appropriate antibiotic treatment: A retrospective multicenter study in Korea
por: Kim, Tark, et al.
Publicado: (2018)

Risk Factors for Mortality in Patients with Acinetobacter baumannii Bacteremia
por: Park, Se Yoon, et al.
Publicado: (2013)

Clinical impact of COVID-19 in patients with carbapenem-resistant Acinetobacter baumannii bacteraemia
por: Kim, Jeong Yeon, et al.
Publicado: (2023)

Survival of carbapenem-resistant Acinetobacter baumannii bacteremia: colistin monotherapy versus colistin plus meropenem
por: Park, So Yeon, et al.
Publicado: (2019)

581. The Epidemiology of Imipenem-Resistant Acinetobacter baumannii Bacteremia in a Pediatric Intensive Care Unit and Carbapenem Use
por: Kim, Dongsub, et al.
Publicado: (2019)

Is Polymicrobial Bacteremia an Independent Risk Factor for Mortality in Acinetobacter baumannii Bacteremia?
por: Wang, Yung-Chih, et al.
Publicado: (2020)

Development of Novel Peptides for the Antimicrobial Combination Therapy against Carbapenem-Resistant Acinetobacter baumannii Infection
por: Choi, Joonhyeok, et al.
Publicado: (2021)

Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia; retrospective study of impact of combination antimicrobial therapy
por: Kim, Youn Jeong, et al.
Publicado: (2014)

Nosocomial Outbreak of Carbapenem-Resistant Acinetobacter baumannii in Intensive Care Units and Successful Outbreak Control Program
por: Choi, Won Suk, et al.
Publicado: (2010)

Molecular and virulence characteristics of carbapenem-resistant Acinetobacter baumannii isolates: a prospective cohort study
por: Park, Seung Min, et al.
Publicado: (2023)

Carbapenem Breakpoints for Acinetobacter baumannii Group: Supporting Clinical Outcome Data from Patients with Bacteremia
por: Lee, Yi-Tzu, et al.
Publicado: (2016)

Effects of Group 1 versus Group 2 Carbapenems on the Susceptibility of Acinetobacter baumannii to Carbapenems: A Before and After Intervention Study of Carbapenem-Use Stewardship
por: Yoon, Young Kyung, et al.
Publicado: (2014)

Colistin, Hot Potato for the Therapy of Carbapenem-resistant Acinetobacter baumannii infections
por: Park, Sang-Won
Publicado: (2019)

Clinical Outcomes and Safety of Meropenem–Colistin versus Meropenem–Tigecycline in Patients with Carbapenem-Resistant Acinetobacter baumannii Pneumonia
por: Park, Jae-Min, et al.
Publicado: (2021)

The Clinical Characteristics, Carbapenem Resistance, and Outcome of Acinetobacter Bacteremia According to Genospecies
por: Park, Kyung-Hwa, et al.
Publicado: (2013)

Risk factors for multi-drug resistant Acinetobacter baumannii bacteremia in patients with colonization in the intensive care unit
por: Jung, Ji Ye, et al.
Publicado: (2010)

Molecular mechanism of antimicrobial activity of chlorhexidine against carbapenem-resistant Acinetobacter baumannii
por: Biswas, Deepika, et al.
Publicado: (2019)

Evolution of Acinetobacter baumannii in Clinical Bacteremia Patients
por: Li, Henan, et al.
Publicado: (2021)

In vitro synergistic antimicrobial activity of a combination of meropenem, colistin, tigecycline, rifampin, and ceftolozane/tazobactam against carbapenem-resistant Acinetobacter baumannii
por: Ju, Yong Guk, et al.
Publicado: (2022)

813. The Reduction of the acquisition rate of carbapenem resistant Acinetobacter baumannii after room privatization in the intensive care unit
por: Jung, Jongtak, et al.
Publicado: (2020)

Antiseptic 9-Meric Peptide with Potency against Carbapenem-Resistant Acinetobacter baumannii Infection
por: Krishnan, Manigandan, et al.
Publicado: (2021)

Biofilm formation is not an independent risk factor for mortality in patients with Acinetobacter baumannii bacteremia
por: Chiang, Tsung-Ta, et al.
Publicado: (2022)

Association of capsular types with carbapenem resistance, disease severity, and mortality in Acinetobacter baumannii
por: Hsieh, Yu-Chia, et al.
Publicado: (2020)

Carbapenem-Resistant Acinetobacter baumannii in U.S. Hospitals: Diversification of Circulating Lineages and Antimicrobial Resistance
por: Iovleva, Alina, et al.
Publicado: (2022)

Colistin Plus Carbapenem versus Colistin Monotherapy in the Treatment of Carbapenem-Resistant Acinetobacter baumannii Pneumonia
por: Shi, HyeJin, et al.
Publicado: (2019)

Molecular and Epidemiological Characterization of Carbapenem-Resistant Acinetobacter baumannii in Non-Tertiary Korean Hospitals
por: Park, Sunok, et al.
Publicado: (2013)

Initial indicators for the prognosis of Acinetobacter Baumannii bacteremia in children
por: Hong, Yi, et al.
Publicado: (2023)

Synergistic Effects of a Probiotic Culture Extract and Antimicrobial Combinations against Multidrug-Resistant Acinetobacter baumannii
por: Lee, Ji Hyeon, et al.
Publicado: (2023)

Whole-Genome Sequencing for Investigating a Health Care-Associated Outbreak of Carbapenem-Resistant Acinetobacter baumannii
por: Hwang, Sang Mee, et al.
Publicado: (2021)

Quantitative proteomics to study carbapenem resistance in Acinetobacter baumannii
por: Tiwari, Vishvanath, et al.
Publicado: (2014)

Carbapenem-resistant Acinetobacter baumannii outbreak at university hospital
por: Takagi, E.H., et al.
Publicado: (2009)

Fanny pack transmission of carbapenem-resistant Acinetobacter baumannii
por: DelleFave, Amber, et al.
Publicado: (2023)

Risk factors for progression to bacteremia among patients with nosocomial carbapenem-resistant Acinetobacter baumannii pneumonia in the Intensive Care Unit
por: Niu, Haiming, et al.
Publicado: (2023)

Assessment of Effective Antimicrobial Regimens and Mortality-Related Risk Factors for Bloodstream Infections Caused by Carbapenem-Resistant Acinetobacter baumannii
por: Gu, Shumin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_c5t812jugvtbqktull3bs21tla